Answers are grounded in this paper and cite their sources.
The short bowel syndrome with intestinal failure (SBS-IF) is a rare but devastating medical condition. An absolute loss of bowel length forces the patients into parenteral support (PS) dependency and a variety of medical sequalae resulting in increased morbidity and mortality. Interdisciplinary treatment may include therapy with the effective, but expensive intestinotrophic peptide teduglutide. A time-discrete Markov-model was developed to simulate the treatment effect (lifetime-costs, quality-adjusted life-years (QALYs) and life-years (LYs)) of teduglutide plus best supportive care (BSC) compared with BSC alone in SBS-IF patients. The health states of the model were structured around the number of days on PS. Clinical data from three data sets were used: (1) an Austrian observational study (base case) (2) pooled observational cohort studies and (3) the prospective STEPS studies. Direct and indirect costs were derived from published sources. QALYs, LYs and costs were discounted (3% per annum). Under the base case assumption teduglutide is associated with costs of 2,296,311 € per patient and 10.78 QALYs (13.74 LYs) over a lifetime horizon. No teduglutide is associated with 1,236,816 € and 2.24 QALYs (8.57 LYs). The incremental cost-utility ratio (ICUR) amounts to 123,945 €. In case of the pooled clinical data set, the ICUR increases to 184,961 €. If clinical data based on the STEPS studies were used, the ICUR increased to 235,612 €. Teduglutide in treating SBS-IF patients meets the traditional cost-effectiveness criteria from a European societal perspective. Nevertheless, the varying levels of teduglutide efficacy leave a degree of uncertainty to the calculations.
No takes yet. Share an insight, caveat, or question.
Walter et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: